On October 31, 2017 bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for serious genetic diseases and T cell-based immunotherapies for cancer, reported that members of the management team will present at the following investor events in November (Press release, bluebird bio, OCT 31, 2017, http://investor.bluebirdbio.com/news-releases/news-release-details/bluebird-bio-announces-ash-abstract-conference-call-november-1st [SID1234521373]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

ASH Abstract Data Conference Call and Webcast on Wednesday, November 1, 8:30 a.m. ET. Investors may listen to the call by dialing (844) 825-4408 from locations in the United States or (315) 625-3227 from outside the United States. Please refer to conference ID number 3795968.
Credit Suisse 26th Annual Healthcare Conference, Tuesday, November 7, 2:45 p.m. MT at The Phoenician, Scottsdale, Arizona.
Evercore ISI Biopharma Catalyst/Deep Dive Conference, Wednesday, November 29, 12:50 p.m. ET at the Boston Harbor Hotel, Boston.
Barclays Gene Editing and Gene Therapy Summit, Thursday, November 30, 1:20 p.m. ET at Barclays offices at 745 Seventh Avenue, New York City. This event will not be webcast.
To access the live webcasts of bluebird bio’s presentations, please visit the “Calendar of Events” page within the Investors and Media section of the bluebird bio website at View Source Replays of the webcasts will be available on the bluebird bio website for 90 days following the conference.